Kanis J A, McCloskey E V, Johansson H et al, “A reference standard for the description of osteoporosis”, Bone 2008 Mar;42(3):467-75.
Lewiecki E M, Laster A J, “Clinical review: Clinical Applications of Vertebral Fracture Assessment by Dual-Energy X-Ray Absorptiometry”, J Clin Endocrinol Metab. 2006 Nov;91(11)4215-22.
Watts NB, “The fracture risk assessment tool (FRAX): applications in clinical practice”, J Womens health, 2011;Apr;20(4):525-31.
Huntjens K, van Geel T, van den Bergh J et al, “Fracture Liaison Service: Impact on subsequent nonvertebral fracture incidence and mortality”, J Bone Joint Surg Am, 2014; 96:e29(1-8).
Mirza F, Canalis E, “Secondary osteoporosis: pathophysiology and management”, Eur J Endocrinol. 2015 Sep;173(3):R131-R151.
Devogelaer JP, Goemare S, Boonen S, et al, “Evidence-based guidelines for the prevention and treatment of glucocorticoid- induced osteoporosis: a consensus document of the Belgian Bone Club”, Osteop Int, 2006;Jan;17(1):8-19.
Reginster J, “Antifracture efficacy of currently available therapies for postmenopausal osteoporosis”, Drugs, 2011;71(1);65-78.
Simpson E L, Martyn-St James M, Hamilton J et al, “Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis”, Bone 2020 Jan;130:115081.
Hauselmann HJ, Rizzoli R, “A comprehensive review of treatments for postmenopausal osteoporosis”, Osteop Int, 2003;14:2-12.
Avenell A, Mak JCS, O’Connell D, “Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men (Review)”, Cochrane Database of Systematic Reviews, 2014;Issue 4.
McClung M, Harris S et al, “Bisphosphonate therapy for osteoporosis; benefits, risks and drug holiday”, Am J Med, 2013;Jan;126(1):13-20.
Adler R, Ghada El-Hajj F, Bauer D et al, “Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American society for bone and mineral research”, J Bone Miner Res, 2016;Jan. Vol 31, no 1, 16-35
Wells GA, Cranney A, Peterson J, et al, “Alendronate for the primary and secondary prevention of osteoporotic fractures in post- menopausal women”, Cochrane Database Syst Rev, 2008;Jan23;(1):CD001155. Review.
Wells G, Cranney A, Peterson J, et al, “Risedronate for the primary and secondary prevention of osteoporotic fractures in post- menopausal women”, Cochrane Database Syst Rev, 2008;Jan23;(1):CD004523. Review.
Lyles KW, Colón-Emeric CS, Magaziner JS, et al, “Zoledronic acid and clinical fractures and mortality after hip fracture”, N Engl J Med, 2007;357(18):1799-809.
Devogelaer JP et al, “Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis”, Osteoporos Int, 2007;18(9):1211- 8.
Saito T, Sterbenz J.M. Malam S et al, “Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis”, Osteop Int, 2017;28;3289-3300.
Cummings SR, San Martin J, McClung MR et al, “FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteo- porosis”, N Engl J Med, 2009;361(8):756-65. Erratum in: N Engl J Med. 2009;Nov 5;361(19):1914.
Smith MR, Egerdie B, Hernández Toriz N et al, “Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer”, N Engl J Med, 2009;361(8):745-55.
Stopeck AT, Lipton A, Body JJ et al, “Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study”, J Clin Oncol, 2010;28(35):5132-9.
Kahn A A, Morrison A, Hanley D A et al, “Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus”; J Bone Miner Res. 2015 Jan;30(1):3.23.
Schilcher J, Michaëlsson K, Aspenberg P, “Bisphosphonate use and atypical fractures of the femoral shaft”, N Engl J Med, 2001;362:1728- 37.
Greenspan SL, Bone HG, Ettinger MP, et al, “Treatment of Osteoporosis with Parathyroid Hormone Study Group. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial”, Ann Intern Med, 2007;146(5):326-39.
Cranney A, Papaioannou A, Zytaruk N, et al, “Clinical Guidelines Committee of Osteoporosis Canada. Parathyroid hormone for the treatment of osteoporosis: a systematic review”, CMAJ, 2006;175(1):52-9. Review.
Cranney A, Tugwell P, Zytaruk N,et al, “Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis”, Endocr Rev, 2002;Aug;23(4):524-8. Review.
Cosman F, Crittenden D B, Ferrari S et al, “FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab”, J Bone Miner Res. 2018 Jul;33(7)1219-1226.
Fang Lv, Xiaoling c, Wenjia Y et al, “Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis”, Bone 2020 Jan;130:115121.
Läkemedelsverkets rekommendationer: Läkemedel vid osteoporos för att förhindra benskörhetsfrakturer - behandlingsrekommendation Läkemedelsverket Läkemedelsverket (lakemedelsverket.se)
